Ocular Therapeutix Inc. Common Stock (OCUL)
Stock · NASDAQ · Health Care
$6.87as of 10/16/2026
Price chart
Active signals
OCUL Signal Track Record
How signals performed across all stocks →What OCUL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | 0.0% | 48% | September 16, 2026 |
| Bollinger Band Breakout | 29 | +3.8% | 62% | August 12, 2026 |
| Bollinger Band Breakdown | 20 | -0.7% | 45% | September 16, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -4.9% | 40% | September 16, 2026 |
| Any 20-session window (baseline) | +1.3% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunc…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 325
- Website
- www.ocutx.com/
Fundamentals
- 1-day range
- $7.38$7.68
- Market cap
- $1.92B
- P/E (trailing)
- —
- P/E (forward)
- -5.19
- EPS (trailing)
- $-1.41
- Dividend yield
- —
- Beta
- 1.19
- Avg. volume
- 2.81M
How Ocular Therapeutix Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 5, 2026 · via SEC EDGAR / Finnhub
Forecasts
11 analyst ratings
Ocular Therapeutix Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- OCULOcular Therapeutix Inc. Common Stock$6.87▼ 6.91%Market cap $1.92BP/E —$6.23$16.44
- ABCLAbCellera Biologics Inc. Common Shares$11.8▼ 6.94%Market cap $1.92BP/E —$2.75$15.02
- AGIOAgios Pharmaceuticals Inc. Common Stock$31.32▼ 3.09%Market cap $1.91BP/E —$22.24$46
- NAMSWNewAmsterdam Pharma Company N.V. Warrant$9▼ 17.81%Market cap $1.87BP/E —$9.79$30.45
- ANIPANI Pharmaceuticals Inc.$72.29▲ 0.01%Market cap $1.86BP/E 15.16$69.58$97
- DMRADamora Therapeutics Inc. Ordinary Shares$18.44▼ 1.60%Market cap $1.84BP/E —$16.5$34.89
- NBTXNanobiotix S.A. American Depositary Shares$21.3▼ 4.18%Market cap $1.83BP/E —$13.1$47.66
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| OCUL Ocular Therapeutix Inc. Common Stock | $1.92B | — | $6.87 | ▼ 6.91% | $6.23$16.44 |
| ABCL AbCellera Biologics Inc. Common Shares | $1.92B | — | $11.8 | ▼ 6.94% | $2.75$15.02 |
| AGIO Agios Pharmaceuticals Inc. Common Stock | $1.91B | — | $31.32 | ▼ 3.09% | $22.24$46 |
| NAMSW NewAmsterdam Pharma Company N.V. Warrant | $1.87B | — | $9 | ▼ 17.81% | $9.79$30.45 |
| ANIP ANI Pharmaceuticals Inc. | $1.86B | 15.16 | $72.29 | ▲ 0.01% | $69.58$97 |
| DMRA Damora Therapeutics Inc. Ordinary Shares | $1.84B | — | $18.44 | ▼ 1.60% | $16.5$34.89 |
| NBTX Nanobiotix S.A. American Depositary Shares | $1.83B | — | $21.3 | ▼ 4.18% | $13.1$47.66 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 1 Cash-Burning Stock for Long-Term Investors and 2 Facing HeadwindsYahoo · 10/9/2026
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/9/2026
- Top 4 Healthcare Stocks Backed by Raymond James AnalystsYahoo · 10/8/2026
- Ocular Therapeutix, Inc. (OCUL) Presents at Euretina 2026 - SlideshowSeekingAlpha · 10/6/2026
- Top 3 Health Care Stocks Which Could Rescue Your Portfolio This QuarterBenzinga · 10/6/2026
- 3 Stocks Under $10 That Fall ShortYahoo · 10/5/2026
- Stocktwits Pharma Pulse: Roche Faces FDA Decision, Gene-Therapy Stocks Step Into Focus — The Week’s Biotech WatchlistYahoo · 10/5/2026
- Ocular Therapeutix (OCUL) Stock Still Looks Pricey As 145% Gain Draws ScrutinyYahoo · 10/2/2026
Insider Activity
Insider Actions →- Peter Kaiser · October 2, 2026 · Sale10.0K @ $7.05
- Jeffrey S. Heier · October 2, 2026 · Sale10.9K @ $7.05
- Donald Notman · August 31, 2026 · Sale1.1K @ $10.24
- Pravin Dugel · August 25, 2026 · Gift50.1K
- Peter Kaiser · August 24, 2026 · Sale3.0K @ $10.77
- Sanjay Nayak · August 24, 2026 · Sale1.9K @ $10.78
- Jeffrey S. Heier · August 24, 2026 · Sale3.3K @ $10.78
- Pravin Dugel · August 24, 2026 · Sale21.6K @ $10.77
- Pravin Dugel · June 16, 2026 · Gift50.1K
- Leslie J. Williams · June 10, 2026 · Grant14.0K
- Charles M. Warden · June 10, 2026 · Grant44.0K
- Charles M. Warden · June 10, 2026 · Grant14.0K
- Adrienne L. Graves · June 10, 2026 · Grant44.0K
- Adrienne L. Graves · June 10, 2026 · Grant14.0K
- Jason Shand Robins · June 10, 2026 · Grant14.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 207.47M
- Total value held
- $1.71B
- Institutional holders
- 264
- Unknown32.65M
- Unknown19.69M
- Unknown16.13M
- Unknown12.31M
- Unknown11.88M
- Unknown10.35M
- Unknown8.72M
- Unknown5.90M
- Unknown5.53M
- Unknown4.71M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
OCUL: UBS initiates coverage and Nasdaq grant filing reported
UBS has started coverage of Ocular Therapeutix and set a price target of $14. The company also disclosed inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). OCUL presented its latest data at the Euretina 2026 conference, highlighting ongoing development efforts. Analyst commentary this week varies, with some listing the stock among top healthcare picks while others note its unprofitable status.
OCUL: UBS initiates coverage and Nasdaq grant filing reported. UBS has started coverage of Ocular Therapeutix and set a price target of $14. The company also disclosed inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). OCUL presented its latest data at the Euretina 2026 conference, highlighting ongoing development efforts. Analyst commentary this week varies, with some listing the stock among top healthcare picks while others note its unprofitable status.